Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field

Identificador:  imarina:9432972

Handle: https://hdl.handle.net/20.500.11797/imarina9432972

Autores:  Di Giacomo-Barbagallo, F; Andreychuk, N; Scicali, R; Gonzalez-Lleo, A; Piro, S; Masana, L; Ibarretxe, D

Resumen:
Purpose of the ReviewA significant number of patients fail to achieve target LDL cholesterol (LDL-C) levels. This review aims to explore why inclisiran, a novel class of LLT, should be considered a valuable addition to the current treatment options.Recent FindingsInclisiran is a small interfering RNA (siRNA) that targets PCSK9 synthesis specifically in the hepatocytes. The drug remains in circulation for less than 48 h, but its effect lasts for over six months. Two subcutaneous injections per year consistently lowers LDL-C by approximately 55% with a favorable safety profile. In combination with other LLTs, it can achieve LDL-C reductions of over 80%, supporting its role in high-intensity LLT strategies.SummaryInclisiran represents a novel class of LLT. Administered biannually, reduces baseline LDL-C levels by half. Additionally, it has a strong safety profile. Due to its pharmacokinetic properties, is likely to improve adherence to LLT and persistently maintain low LDL-C levels.